FMP
Silexion Therapeutics LTD
SLXN
NASDAQ
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
0.845 USD
0.021 (2.49%)
SLXN Financial Statements
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Total Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
1.9M
8.04M
1.39M
1.25M
Research and Development
871k
3.22M
766k
961k
Selling, General & Administrative Expenses
1.04M
4.82M
612k
281k
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
1.04M
4.82M
612k
281k
Other Expenses
-12k
0
7k
8k
Operating Income
-1.9M
-8.04M
-1.39M
-1.25M
Total Other Income/Expenses Net
154k
-3.82M
-102k
-168k
Income Before Tax
-1.75M
-11.86M
-1.49M
-1.42M
Income Tax
1k
2k
2k
5k
Net Income
-1.75M
-11.85M
-1.47M
-1.37M
Basic EPS
-0.21
-1.45
-0.18
-0.17
EPS Diluted
-0.21
-1.45
-0.18
-0.17
Basic Average Shares
8.15M
8.15M
8.15M
8.15M
Diluted Average Shares
8.15M
8.15M
8.15M
8.15M
EBITDA
-5.84M
-8.01M
-1.48M
-1.24M
Retained Earning Schedule
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Retained Earnings (Previous Year)
-41.58M
-29.66M
-28.18M
-26.81M
Net Income
-1.75M
-11.85M
-1.47M
-1.37M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-43.25M
-41.58M
-29.66M
-28.18M
Other Distributions
-1.67M
-11.93M
-1.47M
-1.37M
PPE Schedule
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Gross PPE
560k
35k
180k
216k
Annual Depreciation
-12k
22k
7k
8k
Capital Expenditure
0
-16k
0
-6k
Net PPE
572k
29k
173k
214k
Intangible and Goodwill Schedule
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
